Neurology papers, explained by their authors.
JAMA Neurology Author Interviews offers concise, clinically focused discussions with authors of recent neurology investigations. The tone is formal but accessible, moving from study rationale to design, outcomes, and what neurologists may do next.
PRESS PLAY
JAMA Neurology Author Interviews gives neurologic research a direct oral format. The show pairs a structured interviewer with authors of recent JAMA Neurology articles. Episodes usually begin with the clinical problem. Then the conversation narrows. Study design, enrollment criteria, comparator groups, endpoints, and limitations become the real subject. The pacing is academic, but the questions keep the work tied to patient care. Recent episodes spend serious time on stroke medicine, including mechanical thrombectomy, thrombolysis timing, anticoagulation after atrial fibrillation-associated ischemic stroke, and recurrent intracerebral hemorrhage. Migraine care is another recurring lane. Discussions cover fremanezumab for migraine with major depressive disorder and cardiovascular safety questions around anti-CGRP monoclonal antibodies in older adults or adults with disability. The show also reaches into idiopathic intracranial hypertension, where GLP-1 receptor agonists are considered alongside medication use, bariatric surgery, shunting, and optic nerve fenestration. Multiple sclerosis appears through the lens of radiologically isolated syndrome and biomarkers that may help estimate future symptom risk. Huntington disease is treated through a therapeutic question about beta-blocker use and disease onset or progression. The vocabulary is clinical. The aim is clarity. Guests explain why certain populations were included or excluded, why particular scales were chosen, and how methods such as propensity matching or sequential cohort design shape interpretation. The strongest moments come when trial logistics meet real-world medicine, as with delayed study drug starts after thrombolysis or site readiness around anticoagulation timing. It is not a broad wellness program. It is a specialized listen for people who want to hear how neurologists and physician-scientists reason through evidence. The result is closer to an expert journal briefing than a casual medical chat.
Made for: For neurologists, trainees, researchers, and medically fluent listeners who want close readings of clinical neurology studies. It also suits health journalists and evidence-focused clinicians tracking changes in stroke, migraine, MS, and neurodegenerative care.
What sets it apart: The show keeps the article itself at the center, with authors walking through methods, populations, outcomes, and clinical meaning. Its value is the disciplined bridge between peer-reviewed neurology research and bedside decision-making.
Interviews with authors of articles from JAMA Neurology. JAMA Neurology is an international peer-reviewed journal for physicians caring for people with neurologic disorders and those interested in the structure and function of the normal and diseased nervous system.
A migraine trial brings two depression scales; your inner methodology nerd can take notes.
Press play if you want
Short reviews from the PlayNext desk, based on the episodes we processed.
A focused look at how stroke-trial design meets the practical pressures of thrombectomy care.
A stroke-treatment question comes into focus where trial protocol meets the clock. JAMA Neurology Author Interviews has Dr. Cynthia Armand speaking with Dr.
A clinically grounded look at GLP-1 receptor agonists as a possible path in idiopathic intracranial hypertension care.
GLP-1 receptor agonists are framed here as a possible new direction for idiopathic intracranial hypertension, a neurologic condition involving increased intracranial pressure without a structural cause. The episode works best when Dr. Cynthia Armand and Dr.
A careful look at how stroke severity, hemorrhagic risk, and clinical uncertainty shape anticoagulation timing.
Anticoagulation after ischemic stroke from atrial fibrillation comes down to timing: how soon to treat when hemorrhagic risk, stroke severity, and uncertainty all pull in different directions.
Oncology evidence translated into clinical decisions.
Critical care evidence, carefully talked through.
Clinical research, reduced to its practical signal.
Dr.
JAMA Neurology Author Interviews features Dr.
Fremanezumab reduced monthly migraine days and also lowered HAMD-17 and PHQ-9 scores.
Dr.
Jordan Schultz reports that Enroll-HD participants taking beta blockers had lower annualized risk of receiving a motor diagnosis in pre-manifest Huntington disease.
Giovanni Frisoni argues that Alzheimer's should remain a clinical-pathological diagnosis, not a label based on biomarkers alone.
Among 2,000 former football players surveyed, 35% believed they had CTE, a diagnosis confirmed only after death.
An interview with Dr.
Kirsten Bibbins-Domingo discusses becoming editor-in-chief of JAMA and its affiliated journals after work as a physician, epidemiologist, UCSF professor, and U.S.
Interview with lead author discussing a study on erenumab's safety and efficacy for migraine with and without aura.
Interview with Dr.